Phosphate binding efficiency of a polyuronic acid in normal subjects

Area of Science:

• Biochemistry
• Pharmacology
• Nephrology

Background:

• Phosphate binders are crucial for managing hyperphosphatemia in patients with chronic kidney disease.
• Aluminum-free binders are preferred due to safety concerns with aluminum accumulation.
• Sorbiphos is a novel, non-toxic, aluminum-free natural polymer investigated for phosphate binding.

Purpose of the Study:

• To evaluate the in vivo phosphate-binding efficiency of Sorbiphos in healthy volunteers.
• To compare the efficacy of Sorbiphos with a placebo and a known phosphate binder, Alu-Cap.

Main Methods:

• A randomized, placebo-controlled study was conducted with five healthy volunteers (28-34 years old).
• Participants received placebo, 2g Sorbiphos, or 950mg Alu-Cap 30 minutes before a phosphorus load.
• Serum and urinary phosphate levels were measured hourly post-ingestion.

Main Results:

• Both Sorbiphos and placebo showed similar, minor increases in serum and urinary phosphate.
• Alu-Cap resulted in a lesser increase in serum and urinary phosphate compared to Sorbiphos and placebo.
• The observed phosphate binding by Sorbiphos was minimal even at a 2g dose.

Conclusions:

• Sorbiphos demonstrates limited phosphate-binding capacity in healthy individuals with normal renal function.
• Under the tested conditions, Sorbiphos is less effective than Alu-Cap in reducing phosphate absorption.
• Further studies may be needed to explore Sorbiphos efficacy in patient populations or at different dosages.